Another interesting avenue of investigation is related to BBB dysfunction and the subsequent increase in vascular permeability seen in AD [85]; would this increased permeability extend to the ability of ATTR therapies to cross the BBB, and if so, how this would alter the clinical course of AD and other neurodegenerative disorders. Here, TTR is linked to Alzheimer disease.